Abstract:Background: Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (−)- and S (+)-flurbiprofen in human plasma and cerebrospinal fluid (CSF) after intravenous injection of flurbiprofen axetil.Methods: A total of 70 adult patients undergoing elective lower limb surgery under spinal anesthesia were given a single intravenous injection of 100-mg flurbiprofen axetil. The patients were randomly assigned to 10 groups for plasma and CSF sampling at 10 time points (5–50 min) after subarachnoid puncture and before actual spinal anesthesia. R (−)- and S (+)-flurbiprofen and CSF/plasma ratio were determined by liquid chromatography–tandem mass spectrometry.Results: R (−)-flurbiprofen concentration ranged from 2.01 to 10.9 μg/mL in plasma and 1.46–34.4 ng/mL in CSF. S (+)-flurbiprofen concentration ranged from 1.18 to 10.8 μg/mL in plasma and from 2.53 to 47 ng/mL in CSF. In comparison to S (+)-flurbiprofen, R (−)-flurbiprofen concentration was significantly higher in plasma at all time points (p < 0.05) except at 30 or 40 min, and lower in CSF at all time points (p < 0.05) except at 10, 15 and 40 min. Analysis after correcting drug concentration for body mass index also revealed higher plasma and lower CSF R (−)-flurbiprofen concentration. In comparison to S (+)-flurbiprofen, AUC0–50 for R (−)-flurbiprofen was larger in plasma and smaller in CSF (p < 0.05 for both), and accordingly smaller CSF/plasma AUC0–50 ratio (p < 0.05). There was a positive correlation between R (−)-flurbiprofen concentration and S (+)-flurbiprofen concentration in plasma (r = 0.725, p < 0.001) as well as in CSF (r = 0.718, p < 0.001), and a negative correlation between plasma and CSF concentration of S (+)-flurbiprofen (r = −0.250, p = 0.037), but not R (−)-flurbiprofen.Conclusion: Distribution of R (−)- and S (+)-flurbiprofen in plasma and CSF differed significantly. Penetration of R (−)-flurbiprofen into the CNS was lower than S (+)-flurbiprofen.

Population Pharmacokinetic Modeling of Flurbiprofen, the Active Metabolite of Flurbiprofen Axetil, in Chinese Patients with Postoperative Pain

Clinical trial of flurbiprofen axetil in postoperative pain management on orthopedics surgery patients

Absorption Kinetics of Flurbiprofen Axetil Microspheres in Cerebrospinal Fluid: A Pilot Study .

The Comparison of Plasma and Cerebrospinal Fluid R(−)- and S(+)-Flurbiprofen Concentration after Intravenous Injection of Flurbiprofen Axetil in Human Subjects

Population pharmacokinetic model of subcutaneous fentanyl in older acute care patients

Flurbiprofen Axetil for Postoperative Analgesia in Upper Abdominal Surgery: a Randomized, Parallel Controlled, Double-Blind, Multicenter Clinical Study

Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations

Population Pharmacokinetics of Remifentanil when Combined with Propofol Target-Controlled Infusion in Chinese Patients Undergoing Elective Surgery

Pharmacokinetics and pharmacodynamics of intravenous delafloxacin in healthy subjects: model-based dose optimization

Determination of flurbiprofen in rat plasma using ultra-high performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study

Comparison of intravenous ibuprofen pharmacokinetics between Caucasian and Chinese populations using physiologically based pharmacokinetics modeling and simulation

Effect of Flurbiprofen Axetil Pretreatment on Level of Central Β-Endorphin in a Rat Model of Incisional Pain

Perioperative Use of Flurbiprofen Axetil on Renal Function after Transurethral Prostatectomy: A Prospective Randomized Controlled Study

Population total and unbound pharmacokinetics and pharmacodynamics of ciprofol and M4 in subjects with various renal functions

Rapid identification of potential nonsteroidal anti‐inflammatory drug overdose–induced liver toxicity and prediction of follow‐up exposure: Integrating bioanalytical and population pharmacokinetic assay

Development and evaluation of a harmonized whole body physiologically based pharmacokinetic (PBPK) model for flutamide in rats and its extrapolation to humans

Preliminary study on population pharmacokinetic model of metformin sustainedrelease tablets in healthy subjects

Population pharmacokinetic analysis of febuxostat with high focus on absorption kinetics and food effect

Prediction of drug–drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach

Physiologically based modeling of the pharmacokinetics of acetaminophen and its major metabolites in humans using a Bayesian population approach

Population pharmacokinetics of remifentanil in adult patients undergoing elective major abdominal sur-gery